Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Adv Exp Med Biol. 2012;771:1–11. https://doi.org/10.1007/978-1-4614-5441-0_1.

Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23(5):1098–102. https://doi.org/10.1080/13685538.2019.1678126.

Article  CAS  PubMed  Google Scholar 

Aktas G. Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 diabetes mellitus. J Clin Med. 2023;12(18):5952. https://doi.org/10.3390/jcm12185952.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aktas G, Atak Tel BM, Tel R, Balci B. Treatment of type 2 diabetes patients with heart conditions. Expert Rev Endocrinol Metab. 2023;18(3):255–65. https://doi.org/10.1080/17446651.2023.2204941.

Article  CAS  PubMed  Google Scholar 

Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228):443–5.

Article  CAS  PubMed  Google Scholar 

Kjeldsen TB, Hubalek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64(13):8942–50.

Article  CAS  PubMed  Google Scholar 

Gauza MD, Guisso ME, Silva JO, Kohara SK. Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Archives of Endocrinology and Metabolism. 2023;67:e000614.

Cochrane Training. Cochrane handbook for systematic reviews of interventions. Available from https://training.cochrane.org/handbook. Accessed 3 June 2022.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3): e1003583.

Article  PubMed  PubMed Central  Google Scholar 

Lingvay I, Buse JB, Franek E, Hansen MV, Koefoed MM, Mathieu C, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. 2021;44(7):1595–603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Bajaj HS, Janež A, Silver R, Begtrup K, Hansen MV, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–16.

Article  CAS  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

Article  PubMed  Google Scholar 

Nishimura E, Pridal L, Glendorf T, Hansen BF, Hubálek F, Kjeldsen T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1): e002301.

Article  PubMed  PubMed Central  Google Scholar 

Hövelmann U, Brøndsted L, Kristensen NR, Ribel-Madsen R, Devries JH, Heise T, et al. 237-or: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes. 2020;69(Suppl 1):237–OR.

Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144–9.

Article  CAS  PubMed  Google Scholar 

Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9(3):213–7.

PubMed  Google Scholar 

Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9.

Article  PubMed  Google Scholar 

Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735–45.

Article  PubMed  PubMed Central  Google Scholar 

Gentile S, Strollo F, Ceriello A. Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear? Diabetes Ther. 2016;7:401–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400–5.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Miller ME, Byington RP. i wsp. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–59.

Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med. 2013;126(9):S21–7.

Article  CAS  PubMed  Google Scholar 

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, et al. Weekly Icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(4):297–308.

Article  CAS  PubMed  Google Scholar 

Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401(10392):1929–1940. https://doi.org/10.1016/S0140-6736(23)00520-2.

Pieber TR, Arfelt KN, Cailleteau R, et al. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Diabetologia. 2023;66(8):1413–1430. https://doi.org/10.1007/s00125-023-05921-8.

American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73–84

Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000;93(6):369–74.

Article  CAS  PubMed  Google Scholar